Global Premenstrual Syndrome Treatment Market Expected to Reach $1,516 Million by 2026

According to a new report published by Allied Market Research, titled, "Premenstrual Syndrome Treatment Market, by Drug Type, Type and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019–2026," the global premenstrual syndrome treatment market size was valued at $1,129  million in 2018, and is projected to reach $1,516   million by 2026, growing at a CAGR of 3.7% from 2019 to 2026. 

Premenstrual syndrome (PMS) is a condition that affects emotional behavior and physical health of women during or few days before their menstrual cycle. PMS often leads to acne, tender breasts, bloating, irritability, and mood swings , which could be managed by lifestyle changes or drug treatment. Medication such as analgesics, antidepressants, oral contraceptives and ovarian suppression agents are generally used to manage PMS. 

The premenstrual syndrome treatment market is expected to experience a significant growth during the forecast period, owing to rise in demand for PMS treatment medication across the globe and increase in awareness related to PMS. Surge in number of target population is further anticipated to boost the premenstrual syndrome treatment market growth during the forecast period. According to the American Psychiatric Association, almost 90% of women of child bearing age experience premenstrual symptoms. In addition, growth in demand for premenstrual therapeutics in developing countries  further creates opportunities for the premenstrual syndrome treatment market. However, unknown etiology and pathophysiology of PMS and adverse effects associated with off label drugs are anticipated to hamper the market growth. 

By drug type, the market is categorized into analgesics, antidepressants, oral contraceptives & ovarian suppression agents, and others. Presently, analgesics is the major revenue contributing segment and is estimated to show the same dominance during the forecast period, owing to preferable use of Nonsteroidal anti-inflammatory (NSAIDs) as first line treatment in management of PMS. 

According to distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment is anticipated to depict significant growth during the forecast period, due to rise in preference for online purchasing of drugs, increase in awareness of online pharmacies, and rise in number of internet users.

Key Findings of the Study:

• By drug Type, the analgesics segment held more than three forth share in the global market in 2018. 
• By distribution channel, the online providers segment exhibits fastest growth and is expected to grow at a CAGR of 4.9% from 2019 to 2026.  
• By distribution channel, the drug stores & retail pharmacies segment held the largest market share in 2018, and is expected to remain dominant throughout the forecast period.  
• Region wise, Asia-Pacific is expected to experience a significant growth, registering a CAGR of 5.1% during the forecast period. 

North America accounted for approximately one-half of the global premenstrual syndrome treatment market share in 2018, and is expected to remain dominant throughout the forecast period. This was attributed to the rise in higher adoption of premenstrual syndrome treatment medication, rise in PMS treatment awareness among patients, and large number of target population, with wide availability of PMS treatment therapeutics in this region. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period, majorly due to growing number of target population with increase in adoption of premenstrual syndrome treatment medication in the region.